Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Treace Medical Concepts, Inc. (NASDAQ:TMCI) maintains a consensus rating of "Hold" from six brokerages, with an average 12-month price target set at $9.83.
• Institutional investors currently hold 84.08% of Treace Medical Concepts' stock, indicating strong institutional interest and investment in the company.
• In the latest quarterly earnings report, Treace Medical Concepts reported a loss of ($0.28) earnings per share, exceeding the consensus estimate by $0.01, while also forecasting a negative EPS of -0.92 for FY 2025.

Treace Medical Concepts, Inc. (NASDAQ:TMCI - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.8333.

A number of brokerages have issued reports on TMCI. UBS Group reaffirmed a "neutral" rating and issued a $6.50 target price (down from $8.60) on shares of Treace Medical Concepts in a research report on Friday, August 8th. Stifel Nicolaus cut their target price on Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating on the stock in a research report on Friday, August 8th.

Hedge Funds Weigh In On Treace Medical Concepts

A number of institutional investors have recently made changes to their positions in TMCI. Wells Fargo & Company MN raised its position in shares of Treace Medical Concepts by 45.6% in the 4th quarter. Wells Fargo & Company MN now owns 24,796 shares of the company's stock valued at $184,000 after purchasing an additional 7,769 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Treace Medical Concepts by 217.3% during the fourth quarter. Renaissance Technologies LLC now owns 112,000 shares of the company's stock worth $833,000 after purchasing an additional 76,700 shares during the last quarter. Raymond James Financial Inc. bought a new position in Treace Medical Concepts during the fourth quarter worth $392,000. Stifel Financial Corp lifted its stake in Treace Medical Concepts by 41.5% during the fourth quarter. Stifel Financial Corp now owns 189,301 shares of the company's stock worth $1,408,000 after purchasing an additional 55,540 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Treace Medical Concepts by 22.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,056 shares of the company's stock worth $142,000 after purchasing an additional 3,452 shares during the last quarter. 84.08% of the stock is owned by institutional investors and hedge funds.

Treace Medical Concepts Trading Down 0.3%

Shares of NASDAQ:TMCI traded down $0.02 during trading on Tuesday, reaching $7.40. 255,578 shares of the stock were exchanged, compared to its average volume of 423,150. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.52. Treace Medical Concepts has a 12-month low of $4.54 and a 12-month high of $10.79. The firm has a market cap of $467.46 million, a price-to-earnings ratio of -9.37 and a beta of 0.68. The firm's 50-day moving average price is $6.18 and its 200 day moving average price is $7.02.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. The firm had revenue of $47.39 million during the quarter, compared to analysts' expectations of $47.08 million. Treace Medical Concepts had a negative return on equity of 46.76% and a negative net margin of 23.01%. Treace Medical Concepts has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Treace Medical Concepts will post -0.92 earnings per share for the current fiscal year.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.